Pet subject for Dechra as group looks to US

The group, which has its Dales Pharmaceuticals plant in Skipton making drugs for pets and humans, added it has started its new financial year well and in line with its expectations, with first quarter sales up 3.6 per cent.

Dechra added it has negotiated a 78m bank facility to replace its existing facilities.

"The board remains confident that the group will continue to make good strategic progress in line with management expectations throughout the remainder of the financial year," it said.

The group's European pharmaceuticals division continued to make "good progress" with first quarter revenue 4.9 per cent higher than a year ago.

However, sales from its US pharmaceuticals arm slumped 16.9 per cent on a year ago on supply issues.